Zim Laboratories Ltd Share Price

Zim Laboratories
Small Cap | Pharmaceuticals
₹ No value
Last updated: 27-Sep-2025 , 5 min delay

Zim Laboratories Ltd Live Price Chart

Low: ₹0 High: 0
Open Your Trading & Demat Account
+91

Zim Laboratories Ltd Technicals

Current Price
₹ No value
EMASMA
20 Day ₹ 75.872
50 Day ₹ 82.588
100 Day ₹ 88.705
200 Day ₹ 94.167
20 Day ₹ 75.114
50 Day ₹ 85.250
100 Day ₹ 93.435
200 Day ₹ 94.780

Zim Laboratories Ltd Performance

Previous Close ₹
High ₹
Volume 47692
52W Range ₹ 69.1 - ₹ 128
Open ₹
Low ₹
Market Cap 356.87 Cr

Zim Laboratories Ltd Fundamentals

ROCE 8.004
P/E Ratio 38.410
P/B Ratio 1.470
Industry P/E 1.470
Debt to Equity 38.991
ROE 4.803
EPS 1.910
Dividend Yield 0.000
Book Value 49.904
Face Value 10.000

Zim Laboratories Ltd Financials

Particulars Y202503 Y202403 Y202303 Y202203 Y202103
Total Revenue 381.2564 370.1642 402.9619 333.9999 306.0784
Total Expenses 363.6443 347.1245 367.0439 314.7033 292.3175
Profit After Tax 11.744 16.7555 25.0088 13.0128 5.6162

Zim Laboratories Ltd Shareholding Pattern

Promoter Holdings 33.264 %
FIIs 0.034 %
DIIs 0.238 %
MutualFund 0.000 %
Retail 47.500 %
Others - 18.964 %

About Zim Laboratories Ltd

History of Zim Laboratories Ltd

Zim Laboratories Ltd was incorporated in February, 1984 under the name and style of Zim Laboratories Private Limited in the State of Maharashtra. The Company became a Public Limited Company through fresh Certificate of Incorporation issued by the Registrar of Companies, Maharashtra, Mumbai. The Company is engaged in the manufacturing of formulation on drugs and pre formulation ingredients in India and marketing and selling these within and outside India. The Pharma Industry is dominated by Multinationals, Large Indian companies and in the lower end of the market large number of units mainly in the SSI sector. During the year 2019-20, ZIM Health Technologies Limited was acquired thereby resulting as a wholly owned subsidiary of the company . SIA ZIM Laboratories Limited got incorporated ...

Similar Stocks

Company 52 Week Market Price P/E Ratio
Albert David Ltd ₹ 762.6 - ₹ 1540 0.00 70.75
Orchid Pharma Ltd ₹ 603.8 - ₹ 1997.4 0.00 38.25
Dr Reddys Laboratories Ltd ₹ 1020 - ₹ 1405.9 0.00 15.17
Jagsonpal Pharmaceuticals Ltd ₹ 158.62 - ₹ 328.04 0.00 23.49
Lyka Labs Ltd ₹ 93 - ₹ 176.59 0.00 46.59

FAQs on Zim Laboratories Ltd

1. Can I buy Zim Laboratories Ltd from PL Capital? ›

Yes, you can invest in Zim Laboratories Ltd shares directly through PL Capital. Our platform provides a seamless and secure way to buy, hold, and track Zim Laboratories Ltd stock along with other leading companies listed on the NSE and BSE. Simply open a Demat and trading account with PL Capital, and you’ll be able to trade Zim Laboratories Ltd as well as diversify your portfolio across equities, mutual funds, IPOs, and more.

2. Does Zim Laboratories Ltd pay dividends? ›

Zim Laboratories Ltd does not currently pay dividends. Investors in this case primarily benefit from capital appreciation, where the value of the stock may rise over time depending on business growth and market conditions.

3. What is the current share price of Zim Laboratories Ltd ? ›

As of 26-09-2025 the share price for Zim Laboratories Ltd. is 73.23 on the NSE (Note: Prices are dynamic and update frequently during market hours).

4. What is the 52-week high and low of Zim Laboratories Ltd ? ›

The 52-week high and low of Zim Laboratories Ltd share price is ₹ 69.1 - ₹ 128 as of 26-09-2025 .
PL Ringside View

Our fireside chat series where industry experts and top management share valuable insights for our clients

Youtube

Mark Mobius on India’s Growth, Global Markets, and Investment Opportunities

Youtube

₹100 cr net profit in 7-12 months | Anjali Nashier, Revolt Motors

Youtube

India's Path to Energy Security | Dr. Praveer Sinha, MD & CEO, Tata Power

  • PL Capital Logo

  • Regd. Office : 3rd Floor, Sadhana House,
    570, P. B. Marg, Behind Mahindra Tower,
    Worli, Mumbai - 400 018, India

    View on Google Maps

  • Tel. : 02266322222

    Call us

Prabhudas Lilladher Private Limited | CIN: U67190MH1983PTC029670 | Registered Office Address: 3rd Floor, Sadhana House, 570, P.B. Marg, Worli, Mumbai – 400018, Maharashtra, India | SEBI Registration Details: Stock Broking: INZ000196637 [Membership Codes: NSE – 05977; BSE – 564; MCX – 40690] | Depository Participant: IN-DP-439-2019 [DP Codes: CDSL – 12011300; NSDL – IN303868 | Portfolio Management: INP000009001| Research Analyst: INZ000000271 | Investment Advisors: INA000018267 [BSEASL Membership Code: BASL2042] | AMFI ARN: 3276 | Compliance Officer: Mrs. Snehal Kathrani; Tel: 02266322420; email: co@plindia.com | For any Grievance/ Dispute: Stock Broking; email: grievance-br@plindia.com; Tel: 02266322366; Depository Participant; email: grievance-dp@plindia.com; Tel: 02266322452; Portfolio Management; email: grievance-pms@plindia.com; Tel: 02266322350.

To register your grievance on SCORES log onto: https://scores.gov.in/scores/Welcome.html. Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, Email ID

To register your grievance on Smart ODR Portal log onto: Online Dispute Resolution Portal (ODR Portal).

Standard Disclaimers: (a) Investment in securities market are subject to market risks, read all the related documents carefully before investing. (b) Brokerage will not exceed the SEBI prescribed limits. (c) Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

The brand name and Logo ‘PL Capital’ are the registered trademarks of Prabhudas Lilladher Advisory Services Private Limited which is the holding company of Prabhudas Lilladher Group of Companies .

Prabhudas Lilladher Private Limited is not associated with any unregulated platform which claims performance/return for algorithmic strategy for trading. Trading with unregulated platforms for algorithmic strategy shall be at your own risk and Prabhudas Lilladher Private Limited or its affiliates shall not be liable for the same.

Risk Disclosure on Derivatives: (a) 9 out of 10 individual traders in equity futures and options segment, incurred net losses. (b) On an average, loss makers registered net trading loss close to ₹ 50,000 (c) Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs. (d) Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source